Big Pharma-Biotech Dealmaking: Less Prolific, More Expensive
While each year seems to bring Big Pharma/Biotech deals of record-breaking valuations, on the whole, these deals have steadily declined since 1997, according to statistics presented in this month's Allliance Watch.
You may also be interested in...
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Likelihood of webcast-only advisory committee meetings may depend on the extent of the coronavirus outbreak, Office of New Drugs Director Peter Stein tells the Pink Sheet in an interview.